Edwards Lifesciences (NYSE:EW) VP Donald Bobo, Jr. Sells 24,000 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Edwards Lifesciences Price Performance

Shares of EW traded up $2.43 on Thursday, hitting $85.83. The company’s stock had a trading volume of 3,707,770 shares, compared to its average volume of 5,066,583. The company has a market capitalization of $49.81 billion, a PE ratio of 46.90, a PEG ratio of 2.18 and a beta of 0.94. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a 50 day moving average price of $82.70 and a 200 day moving average price of $81.13. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the subject of several research reports. Piper Sandler restated an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 12th. BTIG Research reissued a “buy” rating and issued a $103.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a report on Monday, November 3rd. Finally, UBS Group reiterated a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the business. MidFirst Bank acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $298,000. Kera Capital Partners Inc. grew its position in Edwards Lifesciences by 8.8% in the fourth quarter. Kera Capital Partners Inc. now owns 6,006 shares of the medical research company’s stock valued at $489,000 after purchasing an additional 488 shares in the last quarter. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $26,000. Compound Planning Inc. lifted its position in Edwards Lifesciences by 20.9% during the 4th quarter. Compound Planning Inc. now owns 3,921 shares of the medical research company’s stock worth $334,000 after buying an additional 678 shares in the last quarter. Finally, Harbour Wealth Management Group Inc. acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $237,000. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.